MedTrace Logo

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

NCT03022565 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2020-02-06

No results posted yet for this study

Summary

This proof-of-concept study will evaluate the ability of vorinostat to induce the transformation of Class 2 uveal melanoma cells into a cell phenotype that resembles normal melanocytes.

Conditions

Interventions

DRUG

Vorinostat

Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.

Sponsors & Collaborators

  • University of Miami Sylvester Comprehensive Cancer Center

    collaborator OTHER

  • University of Miami

    lead OTHER

Principal Investigators

  • J. William Harbour, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2020-01-29
Completion
2020-01-29
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03022565 on ClinicalTrials.gov